Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
High blood glucose levels in hospitalized patients with diabetes are associated with
increased risk of medical complications. Improved glucose control with insulin injections may
improve clinical outcome and prevent some of the hospital complications. It is not known;
however, what is the best insulin regimen in hospitalized patients. Recently, the use of
basal/bolus insulin therapy with detemir (Levemir®) and rapid-acting insulin (lispro, aspart,
glulisine) has been shown to facilitate outpatient glycemic control with lower rate of
hypoglycemic (low blood sugar) events in patients with diabetes. In this study, we will
determine the efficacy and safety of the combination of detemir and aspart insulin in the
inpatient management of subjects with diabetes. We hypothesize that in patients with type 2
diabetes admitted to general medicine wards, treatment with insulin detemir once daily plus
insulin aspart before meals will allow better glycemic control and lower rate of hypoglycemic
events than treatment with twice a day NPH plus regular insulin before meals. Detemir is a
long-acting insulin which is given subcutaneously (under the skin) once daily. Aspart is a
rapid-acting insulin which is given subcutaneously several times a day and frequently before
meals. Detemir and aspart insulins are approved for use in the treatment of patients with
diabetes by the FDA.
This investigator-initiated research will be conducted at Grady Memorial Hospital, Atlanta
and at Rush University Medical Center, Chicago, IL. Dr. Umpierrez designed the study and will
serve as principal investigator. A total of 65 patients will be recruited at Grady and 65
patients at the Rush University Medical Center, Chicago, IL.